STRATUSTM
ANALYSIS
MODULE

cloud based uploading and analysis tool

CLINICAL
ANNOTATION &
REPORTING MODULES

identify therapeutic options

MOLECULAR
TUMOR BOARD
MODULE

provide clinical interpretation of results

TOMA’s mission is to provide the most effective sequencing solution to identify clinically meaningful changes in the DNA of cancer tumors.

TOMA has commercially launched TOMA OS-SeqTM Cancer Assay to help laboratories and researchers uncover clinically meaningful genomic changes in tumors, including many missed by other methods.

With an exclusive license to the oligo selective sequencing (OS-Seq) technology invented at Stanford University, TOMA has developed a fast, simple and efficient way to comprehensively analyze all types of tumor samples – even those with limited volume and poor quality.

A team of renowned industry specialists is leading the product development, commercialization and regulatory pathways to bring these products to laboratories, hospital systems and research institutions around the world.